Milnacipran (Savella)

What it treats

Milnacipran is approved by the U.S. Food and Drug Administration for fibromyalgia in adults. It is not approved in the US for depression or anxiety, though it's approved for depression in many other countries (Europe, Japan) and is used off-label for depression in the US at times.

For fibromyalgia, milnacipran can reduce pain and improve function alongside non-drug treatments (exercise, sleep hygiene, cognitive-behavioral therapy). The effect is often modest and not everyone responds.

How it works

Milnacipran is a serotonin-norepinephrine reuptake inhibitor, an SNRI. Nerve cells in the brain and spinal cord pass messages using chemical messengers, and serotonin and norepinephrine are two of them. After a cell releases one of these messengers, it normally reabsorbs much of it, a process called reuptake. Milnacipran slows the reuptake of both, so more of each stays available between cells.

For pain conditions like fibromyalgia, the norepinephrine effect at the level of the spinal cord is thought to be part of what helps: it strengthens the descending pathways the brain uses to dampen incoming pain signals.

Receptor mechanism (detail)

Milnacipran is a balanced SNRI with roughly equal serotonin and norepinephrine reuptake inhibition. Levomilnacipran, its more NET-preferring cousin, was developed later. Clinically, milnacipran is used for the pain and fatigue of fibromyalgia rather than as a primary antidepressant in the US.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Starting dose is 12.5 mg once on day 1, then 12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4 through 7, then 50 mg twice daily thereafter. The maximum is 100 mg twice daily (200 mg per day).

Safety monitoring

• Blood pressure and heart rate at baseline, at each visit early on, and periodically. Milnacipran raises both.
• Suicidality in the first 4 weeks, especially under age 25 (FDA boxed warning, on the fibromyalgia label as well).
• Serotonin syndrome, avoid MAOIs.
• Bleeding risk with NSAIDs or anticoagulants.
• Liver function if signs of injury develop.
• Urinary hesitancy or retention.
• Sexual function.
• Discontinuation, taper slowly.

What to expect

For fibromyalgia, the effect on pain and function can take several weeks to develop. Improvements are often modest rather than dramatic. It works best combined with exercise and other non-drug approaches.

Early side effects tend to include nausea, sweating, and sometimes a mild heart-racing feeling. Many settle over the first week or two.

Common side effects

Most people get some side effects. The common ones include:

• Nausea, often the most noticeable early on.
• Constipation.
• Hot flushes.
• Increased sweating.
• Vomiting.
• Palpitations or increased heart rate.
• Dry mouth.
• High blood pressure.
• Sexual side effects.
• Urinary hesitancy.

Many of the stomach-related effects ease within one to two weeks. Sweating and sexual side effects tend to last as long as the medication is taken.

Serious side effects and warnings

Serious problems are uncommon, but a few are worth knowing.

Boxed warning. Milnacipran carries an FDA boxed warning about suicidal thoughts and behaviors, on the theory that all serotonin-affecting antidepressants share this signal in children, teenagers, and young adults under 25. This is a formal note on the fibromyalgia label. Any worsening of mood, agitation, or new thoughts of self-harm should prompt contact with the prescriber promptly.

• Raised blood pressure and heart rate. Milnacipran raises both more than SSRIs do. Blood pressure and heart rate should be checked before starting and at follow-up.
• Serotonin syndrome. A rare reaction caused by too much serotonin activity. Signs include agitation, a fast heartbeat, high body temperature, shivering, muscle twitching, and confusion. It is a medical emergency.
• Liver injury. Rare, but hepatitis and elevated liver enzymes have been reported. Milnacipran isn't recommended in people with heavy alcohol use because of the combined liver strain.
• Increased bleeding risk. Milnacipran can make bleeding and bruising more likely, especially alongside NSAIDs, aspirin, or blood thinners.
• Urinary retention. More likely in men with prostate enlargement.
• Seizures. Rare, and more likely in people with a seizure history.
• Mood switch in bipolar disorder. In people who have bipolar disorder, milnacipran can sometimes trigger a manic or agitated state.

Sexual side effects

Milnacipran, like other SNRIs, commonly affects sexual function. It can lower sex drive, delay orgasm or make it hard to reach, and cause arousal or erection difficulties. Erectile dysfunction and delayed ejaculation are the more commonly reported effects in men, while women may notice reduced desire and orgasm difficulty.

These effects usually last as long as the medication is taken, rather than fading like nausea does. They are worth raising with a prescriber, because there are real options: lowering the dose, switching to a medication less likely to cause this such as bupropion, or adding another medication to counter it. A small number of people report sexual side effects that continue after stopping the drug. This is uncommon and not well understood, but it is a real phenomenon and worth knowing about before you start.

Weight, appetite, and sleep

Milnacipran is roughly weight-neutral for most people. Some report weight loss early on, tied to the nausea. Marked weight gain isn't a typical feature.

Sleep effects can go either way. Some people feel more wakeful and take it earlier in the day; others don't notice much change.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

Milnacipran comes as tablets, taken twice daily. The starter titration pack builds the dose up over the first week: 12.5 mg on day 1, then to 25 mg total on days 2-3, then to 50 mg total on days 4-7, then to 100 mg total by day 8. Most people settle at 100 to 200 mg per day divided.

Kidney function matters. The dose is lowered in severe kidney impairment.

Missed doses and interactions

If you miss a dose, take it when you remember unless it's close to the next scheduled dose. Don't double up. Because SNRIs can cause discontinuation symptoms when a dose is missed, taking it consistently matters.

Several interactions matter. Milnacipran must not be combined with MAOI antidepressants, and a gap is needed when switching between them. Combining it with other drugs that raise serotonin, such as triptans, tramadol, other antidepressants, or St. John's wort, increases serotonin syndrome risk. NSAIDs and blood thinners add to bleeding risk. Digoxin combined with milnacipran can cause postural hypotension and tachycardia, and the combination is generally avoided.

Milnacipran doesn't go through the liver enzyme system as heavily as some other antidepressants, which limits some interactions. Alcohol adds to the liver strain and isn't recommended, particularly in people with a history of heavy drinking. Give every prescriber and pharmacist a full list of your medications and supplements, including over-the-counter ones.

Stopping and tapering

Milnacipran is not addictive in the usual sense. It doesn't cause cravings or compulsive use. But the body does adjust to it, and stopping suddenly can cause discontinuation symptoms: dizziness, flu-like feelings, irritability, vivid dreams, trouble sleeping, and the brief electrical "brain zap" sensations many people describe.

These symptoms are uncomfortable but not dangerous, and they are more likely the higher the dose and the longer the medication has been taken. The way to avoid them is a gradual taper planned with a prescriber, stepping the dose down over weeks.

Pregnancy and breastfeeding

Data on milnacipran in pregnancy is limited. Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber so the specific risks and benefits can be weighed.

Cost and generic availability

Milnacipran is available as a generic. The brand name is Savella. Generic milnacipran contains the same active medication and works the same way.

Common questions

Why is milnacipran only approved for fibromyalgia in the US? It's approved for depression in many other countries. The FDA never approved it for depression in the US, so the American label covers only fibromyalgia. US prescribers do sometimes use it off-label for depression.

How is milnacipran different from levomilnacipran? Milnacipran is a balanced SNRI (roughly equal serotonin and norepinephrine effect). Levomilnacipran is more norepinephrine-selective. Both raise blood pressure somewhat.

Why check my blood pressure? Milnacipran raises blood pressure and heart rate more than SSRIs do. Baseline and follow-up checks make sure it isn't causing a problem.

Is milnacipran addictive? No, not in the usual sense. It doesn't cause cravings or compulsive use. The body does adapt to it, which is why stopping should be gradual.

Can I drink alcohol while taking it? It isn't formally banned, but it isn't recommended. Milnacipran and alcohol together are harder on the liver, and it's a bad match if you have a history of heavy drinking.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• Should my blood pressure be checked while I take it?
• Which side effects should I call about?
• How long should I plan to take it?
• If we decide to stop it later, how would we do that safely?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Milnacipran (Savella) prescribing information.
• MedlinePlus, U.S. National Library of Medicine. Milnacipran.
• National Institute of Mental Health. Mental health medications.
• American Psychiatric Association. Practice guidelines.
• American College of Rheumatology guidance on fibromyalgia management.